Bill Gates, the foundation’s chairman, has been vocal about the dangers of artificial intelligence. The donation will be invested in A.I. projects to bridge social inequalities.
Anthropic researcher Jacob Coxon quit and posted at X last Tuesday, to over 25 million views, that “No other human activity poses this level of danger.”
Cancer researchers have reported a new strategy that combines bacterial tumor targeting, nutrient deprivation and immune stimulation in a single therapeutic design. The approach uses an engineered conjugate built from L-asparaginase and flagellin, linked to a system that directs the treatment toward calreticulin-bearing cancer cells. In experiments involving Salmonella-mediated tumor therapy, the conjugate enhanced antitumor activity compared with bacterial treatment alone, according to a study published in Cell Death Discovery.
The work addresses a long-standing challenge in cancer therapy: how to make powerful treatments concentrate inside tumors while limiting damage to healthy tissues. Attenuated strains of Salmonella have attracted interest because they can preferentially accumulate in the abnormal environment of solid tumors. Tumors often contain regions with poor oxygen levels, disorganized blood vessels and local immune suppression, conditions that can support bacterial growth. Once inside these sites, therapeutic Salmonella can act as a biological delivery platform and stimulate immune responses against malignant cells.
The researchers focused on calreticulin, a protein normally found inside the endoplasmic reticulum, where it helps regulate calcium storage and protein folding. Under cellular stress, including stress caused by chemotherapy, radiation or other anticancer treatments, calreticulin can move to the outer surface of a cancer cell. There, it functions as an “eat-me” signal, alerting immune cells that the damaged cell should be engulfed. Because surface-exposed calreticulin is associated with immunogenic forms of cell death, it provides a potential molecular address for directing therapeutic agents toward stressed tumor cells.
The experimental construct combines this targeting concept with L-asparaginase, an enzyme already used in clinical oncology, especially in the treatment of acute lymphoblastic leukemia. L-asparaginase breaks down circulating L-asparagine into aspartic acid and ammonia. Some cancer cells, particularly those with limited capacity to synthesize their own asparagine, depend heavily on the amino acid supplied through the bloodstream. Depleting extracellular asparagine can therefore interrupt protein production, trigger metabolic stress and promote cancer-cell death. The enzyme’s effectiveness, however, can be limited by immune reactions, pharmacological instability and toxicity, making targeted delivery an important goal.
The second component, flagellin, is the structural protein that forms the filament of bacterial flagella. It is also a potent molecular signal for the innate immune system. Immune cells recognize flagellin primarily through Toll-like receptor 5, while intracellular sensing pathways can activate inflammasome components such as NLRC4. These signals can promote the release of inflammatory mediators, stimulate antigen-presenting cells and help convert an immunologically “cold” tumor into one more visible to the immune system. By incorporating flagellin into the therapeutic design, the researchers sought to make the treatment not only directly toxic to tumor cells but also capable of amplifying antitumor immunity.
The study’s central finding was that the calreticulin-targeting L-asparaginase–flagellin conjugate strengthened the antitumor effects of Salmonella-based therapy. Rather than relying on a single mechanism, the treatment brings together several forms of pressure on the tumor. Salmonella can concentrate within the tumor microenvironment, the targeting component can help associate the conjugate with calreticulin-exposing cancer cells, L-asparaginase can deprive vulnerable cells of an essential nutrient, and flagellin can activate immune surveillance. The resulting combination is designed to produce a chain reaction in which metabolic stress and immune stimulation reinforce one another.
This type of combination may be particularly valuable because tumors frequently adapt when exposed to one therapeutic pressure. A cancer cell that survives nutrient deprivation may still be eliminated if immune recognition is intensified. Likewise, an immune response that is too weak to control a tumor may become more effective when bacterial localization and enzyme-mediated damage increase the number of abnormal antigens and danger signals released by dying cells. The researchers’ findings suggest that coordinating these mechanisms can improve the performance of bacteria-assisted cancer treatment in experimental settings.
The approach also reflects a broader shift in cancer research toward programmable biological medicines. Instead of treating bacteria only as infectious threats, scientists are redesigning them as localized delivery vehicles capable of carrying enzymes, immune activators or molecular probes. The advantage is spatial: a therapeutic payload can be produced or concentrated near the tumor rather than distributed uniformly throughout the body. The challenge is equally significant. Any clinical version would need precise control over bacterial attenuation, immune activation, enzyme exposure and potential inflammation, while also demonstrating reliable performance across genetically diverse tumors.
Calreticulin targeting may provide a useful way to address some of that complexity because the protein’s appearance on the cell surface is linked to cellular stress and treatment response. However, the extent and duration of calreticulin exposure can vary between tumor types and individual patients. Future studies will need to determine which cancers are most suitable for this strategy, how calreticulin levels predict treatment response and whether the conjugate can be combined safely with established immunotherapies such as immune-checkpoint inhibitors. Researchers will also need to assess pharmacology, manufacturing consistency and the possibility of immune reactions against the bacterial or enzymatic components.
The findings position the engineered conjugate as a promising experimental platform rather than an immediately available therapy. By merging tumor-homing bacteria with a calreticulin-directed enzyme and an innate immune stimulant, the study illustrates how cancer treatments can be designed to attack malignant cells on multiple biological fronts. If the results are confirmed in further preclinical testing and eventually in carefully controlled clinical trials, this strategy could help turn Salmonella from a passive carrier into an active, multifunctional partner in cancer immunotherapy.
Subject of Research: Calreticulin-targeted L-asparaginase–flagellin conjugate used with Salmonella-mediated cancer therapy.
In an era marked by escalating environmental concerns and surging demand for sustainable construction practices, a groundbreaking study has emerged, shedding new light on an innovative approach to concrete production. Researchers P. Singh, H. Singh, and S. Paruthi have unveiled a transformative method that harnesses industrial waste materials as fine aggregates in alkali-activated concrete cured under ambient conditions. Published recently in Scientific Reports, their work is poised to revolutionize how the concrete industry addresses sustainability and performance criteria simultaneously.
Concrete, the backbone of modern infrastructure, traditionally relies on natural sand as a fine aggregate. However, the extraction of natural sand has increasingly raised environmental alarms due to riverbed degradation, habitat destruction, and rising extraction costs. Against this backdrop, the remarkable potential of industrial waste byproducts to replace natural aggregates has garnered significant attention. Yet, balancing the incorporation of these unconventional materials without compromising structural integrity has remained a critical challenge until now.
The research conducted by Singh and colleagues intricately explores the integration of various industrial wastes, such as fly ash, slag, and other mineral residues, as substitutes for conventional fine aggregates within an alkali-activated binding matrix. Alkali activation, an innovative cementitious technology, utilizes reactive aluminosilicates and alkaline solutions to produce hardened binders. Unlike ordinary Portland cement, alkali-activated materials demonstrate superior durability, chemical resistance, and a drastically reduced carbon footprint, aligning perfectly with global sustainability goals.
Central to their study is the novel concept of “performance-driven utilization,” whereby the selection and proportioning of industrial wastes are carefully optimized to meet stringent mechanical and durability performance metrics. This intelligent design framework transcends empirical mix designs by embracing a data-driven methodology, incorporating physicochemical characterization, microstructural analyses, and advanced mechanical testing. This holistic strategy ensures the resulting concrete not only performs on par with, or surpasses, traditional mixes but also exhibits enhanced sustainability attributes.
One of the study’s key breakthroughs is the successful ambient curing of the alkali-activated concrete. Conventionally, many geopolymers or alkali-activated materials require elevated temperature curing—often limiting scalability and increasing energy consumption. By demonstrating that industrial waste-infused alkali-activated concrete can attain requisite strength and durability characteristics under ambient temperatures, the research paves the way for more energy-efficient, cost-effective, and pragmatic construction applications.
The researchers meticulously characterized the particle size distribution, mineralogical composition, and surface morphology of the industrial wastes employed. These parameters critically influence the reactivity, workability, and bonding characteristics of the concrete. For instance, the incorporation of finely divided fly ash and granulated blast furnace slag not only contributed to filler effects but also participated actively in the binding phase through pozzolanic and latent hydraulic reactions. This synergistic interplay significantly augmented the microstructural densification and reduced porosity.
Mechanical testing revealed that mixes with tailored industrial waste content achieved compressive strengths exceeding 40 MPa after 28 days of ambient curing—a remarkable feat demonstrating the feasibility of these materials for structural applications. Additionally, durability assessments, including resistance to sulfate attack, chloride penetration, and freeze-thaw cycles, indicated superior performance vis-à-vis conventional concrete. Such resilience renders this technology particularly suitable for harsh environmental exposures often encountered in infrastructure projects worldwide.
An intriguing aspect of the study lies in its environmental impact evaluation. Life cycle assessment (LCA) metrics underscored substantial reductions in carbon dioxide emissions, energy consumption, and natural resource depletion relative to standard Portland cement concrete. By valorizing industrial waste streams—often destined for landfills or disposal—the approach inherently embodies the principles of circular economy, waste minimization, and industrial symbiosis.
Furthermore, the scalability and adaptability of this method were highlighted through case studies simulating real-world production scenarios. The versatility to adjust the mix design based on locally available waste materials allows for broad geographic applicability, especially in regions grappling with both waste management challenges and infrastructure development demands. This localization potential not only mitigates transportation-related carbon footprints but also empowers regional economies by converting liabilities into construction assets.
In terms of practical implementation, the researchers advocate for collaboration with industry stakeholders, regulatory bodies, and policymakers to foster technology transfer and standardization. They emphasize the necessity for developing comprehensive guidelines and quality control protocols to ensure consistent material performance across diverse production batches and construction environments. Such coordinated efforts will be instrumental to mainstream adoption and regulatory acceptance.
The study also opens promising avenues for further interdisciplinary research. Investigations into nano-engineered additives, self-healing functionalities, and hybrid composites combining alkali-activated binders with traditional cementitious systems could unlock new frontiers in concrete technology. Moreover, long-term field monitoring and durability trials under various climatic stresses will reinforce confidence in this innovative material system and elucidate performance trends over extended service lives.
Notably, the socio-economic implications of this research cannot be overstated. By lowering the reliance on finite natural sand resources and simultaneously reducing industrial waste accumulation, the construction industry gains a dual advantage: safeguarding ecosystems and diminishing raw material procurement costs. The cumulative effect may contribute to more affordable housing and infrastructure solutions while aligning with global climate action commitments.
As urbanization accelerates and infrastructure demands escalate globally, the urgency for sustainable material innovations intensifies. This pioneering research by Singh, Singh, and Paruthi embodies the transformative potential of science and engineering to challenge conventional paradigms and chart a sustainable pathway forward. By converting industrial detritus into high-performance concrete components through an environmentally benign process, they redefine what is possible in material engineering for the built environment.
In conclusion, the performance-driven utilization of industrial wastes in ambient-cured alkali-activated concrete stands as a beacon of hope and ingenuity amidst pressing environmental and infrastructural challenges. The synergy of material science, structural engineering, and sustainability principles embodied in this study offers a compelling blueprint for the future of concrete technology. As the industry moves towards decarbonization and circularity, such advancements will be instrumental in sculpting resilient, eco-conscious, and economically viable built environments for generations to come.
Subject of Research: Performance-driven utilization of industrial wastes as fine aggregates in ambient-cured alkali-activated concrete.
Article Title: Performance-driven utilization of industrial wastes as fine aggregates in ambient-cured alkali activated concrete.
Article References: Singh, P., Singh, H. & Paruthi, S. Performance-driven utilization of industrial wastes as fine aggregates in ambient-cured alkali activated concrete. Sci Rep (2026). https://doi.org/10.1038/s41598-026-56374-z
This may be stunning news! The infamous climate alarmist Bill Gates now slams the “Doomsday” view of the Climate Change Cult, adopting a surprising change of tone on so-called ‘global warming’ in a setback to the green socialist movement.
For more than ten years, meetings have been held by billionaires described as philanthropists to Reduce the Size of the World’s Population culminating with the 2020-2024 Covid crisis. Recent developments suggest that “Depopulation” is an integral part of the so-called Covid mandates including the lockdown policies and the mRNA “vaccine”.
Pre-COVID Bill Gates spoke of global depopulation in a TED talk to be achieved through elective abortion and vaccines. COVID vaccines are the method causing miscarriages, sterility and cancers.
Bill Gates, on the Jimmy Fallon show, predicted that AI will significantly reduce the need for humans. Gates acknowledged some human activities would remain, like enjoying sports, yet emphasized that tasks such as production and agriculture will increasingly rely on AI, suggesting a potential global depopulation mindset.
Login
